The Mylan version will also probably cost less than list for most people (though Mylan will get their money, just like the generic maker).
Also, you're correct that the price will come down over time. If the FDA had said, "this approval is part of a process that will eventually lower the cost within the next couple of years," then the article would make no sense. That's not what they said when this generic version was released.
The article is not claiming that generic drugs don't reduce prices. It is claiming that the narrative from the FDA, that this approval will reduce costs, is largely false.